High-Content Phenotypic Profiling of Drug Response Signatures across Distinct Cancer Cells

被引:104
作者
Caie, Peter D. [1 ]
Walls, Rebecca E. [2 ]
Ingleston-Orme, Alexandra [1 ]
Daya, Sandeep [1 ]
Houslay, Tom [1 ]
Eagle, Rob [3 ]
Roberts, Mark E. [4 ]
Carragher, Neil O. [1 ]
机构
[1] AstraZeneca R&D Charnwood, Adv Sci & Technol Lab, Loughborough LE11 5RH, Leics, England
[2] AstraZeneca R&D Charnwood, Discovery Stat, Loughborough LE11 5RH, Leics, England
[3] GlaxoSmithKline, Mol Discovery Res, Harlow, Essex, England
[4] Tessella Plc, Abingdon, Oxon, England
关键词
CHALLENGES; RESISTANCE; MODES;
D O I
10.1158/1535-7163.MCT-09-1148
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The application of high-content imaging in conjunction with multivariate clustering techniques has recently shown value in the confirmation of cellular activity and further characterization of drug mode of action following pharmacologic perturbation. However, such practical examples of phenotypic profiling of drug response published to date have largely been restricted to cell lines and phenotypic response markers that are amenable to basic cellular imaging. As such, these approaches preclude the analysis of both complex heterogeneous phenotypic responses and subtle changes in cell morphology across physiologically relevant cell panels. Here, we describe the application of a cell-based assay and custom designed image analysis algorithms designed to monitor morphologic phenotypic response in detail across distinct cancer cell types. We further describe the integration of these methods with automated data analysis workflows incorporating principal component analysis, Kohonen neural networking, and kNN classification to enable rapid and robust interrogation of such data sets. We show the utility of these approaches by providing novel insight into pharmacologic response across four cancer cell types, Ovcar3, MiaPaCa2, and MCF7 cells wild-type and mutant for p53. These methods have the potential to drive the development of a new generation of novel therapeutic classes encompassing pharmacologic compositions or polypharmacology in appropriate disease context. Mol Cancer Ther; 9(6); 1913-26. (C)2010 AACR.
引用
收藏
页码:1913 / 1926
页数:14
相关论文
共 27 条
[1]  
[Anonymous], 1936, P NATL I SCI INDIA, DOI DOI 10.1007/S13171-019-00164-5
[2]   Drug Resistance Caused by Reversion Mutation [J].
Ashworth, Alan .
CANCER RESEARCH, 2008, 68 (24) :10021-10023
[3]   Object-oriented image analysis for high content screening:: Detailed quantification of cells and sub cellular structures with the cellenger software [J].
Baatz, Martin ;
Arini, Nick ;
Schaepe, Arno ;
Binnig, Gerd ;
Linssen, Bettina .
CYTOMETRY PART A, 2006, 69A (07) :652-658
[4]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[5]   Epithelial mesenchymal transition traits in human breast cancer cell lines [J].
Blick, T. ;
Widodo, E. ;
Hugo, H. ;
Waltham, M. ;
Lenburg, M. E. ;
Neve, R. M. ;
Thompson, E. W. .
CLINICAL & EXPERIMENTAL METASTASIS, 2008, 25 (06) :629-642
[6]  
BUBB MR, 1994, J BIOL CHEM, V269, P14869
[7]   Microscopic imaging techniques for drug discovery [J].
Bullen, Andrew .
NATURE REVIEWS DRUG DISCOVERY, 2008, 7 (01) :54-67
[8]   Can cell systems biology rescue drug discovery? [J].
Butcher, EC .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (06) :461-467
[9]   High-content analysis in preclinical drug discovery [J].
Denner, Philip ;
Schmalowsky, Janine ;
Prechtl, Stefan .
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2008, 11 (03) :216-230
[10]   Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds [J].
Feng, Yan ;
Mitchison, Timothy J. ;
Bender, Andreas ;
Young, Daniel W. ;
Tallarico, John A. .
NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (07) :567-578